AKI Biomarkers and Their Relevance

Why New Biomarkers Are Needed

• Identify AKI in its earliest, most treatable stages
• Distinguish between prerenal azotemia, acute tubular necrosis (ATN), AIN, or obstructive causes
• Provide prognostic information (e.g., who will need renal replacement therapy)

1. Filtration-Based Markers

Cystatin C

• A 13-kDa cysteine protease inhibitor produced at a constant rate by all nucleated cells; accumulates in blood when GFR falls, like creatinine but without muscle mass dependence
• Theoretical advantage over creatinine for mild CKD and in elderly/malnourished patients
• Race-free GFR equations using cystatin C alone or combined with creatinine are now preferred
• AKI limitation: A large TRIBE-AKI cardiac surgery cohort found cystatin C was less sensitive than creatinine for AKI detection; thresholds remain undefined. Patients with AKI by both markers had higher rates of dialysis and death
• Confounders: malignancy, HIV infection, corticosteroids, and thyroid hormones elevate cystatin C independent of renal function

Proenkephalin A 119-159 (penKid)

• A peptide derived from enkephalins that correlates with GFR; proposed as a marker of "subclinical AKI" in critical illness
• Elevated penKid in ICU patients is associated with adverse outcomes
• Role in the perioperative setting is still being defined - Miller's Anesthesia

2. Biomarkers of Tubular Cell Damage

Kidney Injury Molecule-1 (KIM-1)

• A type I transmembrane glycoprotein with an immunoglobulin-like and mucin domain; its ectodomain is shed into urine after proximal tubular injury
• KIM-1 mRNA increases more than any other known gene after kidney injury
• Urinary KIM-1 is an earlier diagnostic indicator than plasma creatinine or BUN in multiple preclinical and clinical models
• Key advantage - specificity: KIM-1 expression is virtually kidney-limited; no systemic source detected, giving it superior specificity (vs. NGAL which is also expressed in neutrophils/liver/gut)
• Induced by nephrotoxins including cisplatin, cyclosporine, cadmium, gentamicin, mercury, and chromium
• NGAL is more sensitive at the earliest time points; KIM-1 adds specificity at later time points
• Plasma KIM-1 assays now available and correlate with urinary levels in both AKI and CKD
• Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 227; Miller's Anesthesia, p. 5679

Tubular Enzymuria (GST, NAG)

• Alpha-GST (proximal tubule) and pi-GST (distal tubule) are cytosolic enzymes shed under cellular stress
• N-acetyl-beta-D-glucosaminidase (NAG) is a proximal tubule lysosomal enzyme
• Can reflect increased tubular cell turnover rather than damage specifically - limited clinical utility at present
• Miller's Anesthesia, p. 5678

3. Biomarkers of Tubular Dysfunction (Tubular Proteinuria)

• Beta-2-microglobulin
• Alpha-1-microglobulin
• Retinol-binding protein
• Lysozyme
• Lambda and kappa light chains

4. Biomarkers of Tubular Stress/Adaptive Response

NGAL (Neutrophil Gelatinase-Associated Lipocalin / Lipocalin-2)

• A 25-kDa protein, upregulated in ischemic renal tubular cells; initially identified in neutrophil granules but also induced in renal epithelial cells after injury
• Urinary NGAL rises within 2-6 hours of insult, preceding serum creatinine elevation by 1-3 days - landmark pediatric cardiac surgery studies
• Both plasma and urine NGAL have been studied; associated with adverse outcomes in multiple settings
• Limitation: Serum NGAL is elevated in inflammatory and infective conditions (sepsis, malignancy), reducing specificity; adult perioperative studies have not consistently shown it to predict AKI before creatinine rises
• Henry's, p. 193; Miller's Anesthesia, p. 5679

Interleukin-18 (IL-18)

• A pro-inflammatory cytokine (IFN-gamma-inducing factor); renal IL-18 mRNA is upregulated in the proximal tubule after ischemia-reperfusion, cisplatin toxicity, and autoimmune nephritis
• Urinary IL-18 is elevated in AKI and delayed graft function vs. prerenal azotemia, UTI, CKD, and nephrotic syndrome
• Elevated 1-2 days before serum creatinine; independently predicts mortality
• Henry's, p. 193

Liver Fatty Acid-Binding Protein (L-FABP)

• A 14-15 kDa cytoplasmic protein abundantly expressed in proximal convoluted and straight tubules
• In cisplatin-induced AKI, urinary L-FABP increased within the first 24 hours, while creatinine did not rise until 72 hours
• Studied in CKD, diabetic nephropathy, IgA nephropathy, contrast nephropathy, cardiac surgery, and kidney transplantation
• Henry's, p. 193

5. Cell Cycle Arrest Markers - FDA-Cleared Biomarker Combination

TIMP-2 and IGFBP-7 (NephroCheck)

• Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) and Insulin-like Growth Factor-Binding Protein 7 (IGFBP-7) are both expressed in renal tubular cells and induce G1-phase cell cycle arrest - a protective cellular stress response
• These two markers were selected from 340 putative candidates and validated in multiple studies
• The combined test (TIMP-2) x (IGFBP-7) has received FDA clearance (marketed as NephroCheck) for identifying patients at high risk of moderate-to-severe AKI within 12 hours
• Validation study (420 critically ill patients, 17% endpoint AKI rate):
  • Cutoff of 0.3 (ng/mL)²/1000: 92% sensitivity
  • 7x more likely to develop AKI vs. clinical indicators alone
• AUC of 0.80 in validation cohort for predicting KDIGO stage 2-3 AKI
• Clinical trials have used elevated TIMP-2 x IGFBP-7 to enroll high-risk patients for AKI-prevention protocols (especially cardiac surgery)
• Henry's, p. 193-194; Miller's Anesthesia, p. 5679

Summary Table

Clinical Relevance Summary

1. Early detection: NGAL and KIM-1 can detect tubular injury 1-3 days before creatinine rises - enabling earlier nephroprotective interventions.
2. Etiologic discrimination: IL-18 distinguishes intrinsic AKI (ATN) from prerenal azotemia; KIM-1 is highly specific for ischemic or nephrotoxic injury.
3. Risk stratification: TIMP-2 x IGFBP-7 (NephroCheck) is FDA-cleared for identifying ICU and surgical patients at high short-term risk.
4. Prognostication: Elevated NGAL, IL-18, and cystatin C predict progression to RRT and mortality.
5. Drug toxicity monitoring: KIM-1 and NGAL are validated preclinically by the Predictive Safety Testing Consortium (FDA partnership) for nephrotoxicity screening of new drugs.

Procalcitonin (PCT)

What Is It?

Mechanism of Induction and Suppression

Kinetics

• Rises within 4-6 hours of bacterial infection onset
• Peak can be delayed (especially in localized infections)
• Half-life: approximately 22-35 hours (some sources cite ~24 hours)
• 50% plasma disappearance rate: roughly 1 to 1.5 days
• Falls rapidly with appropriate antimicrobial therapy
• Renal dysfunction: clearance is prolonged, but significant accumulation does not occur
• Kinetics over the first 72 hours of hospitalization are independently associated with patient outcomes

Reference Ranges and Interpretation

Diagnostic Performance

• Bacteremia detection (most common threshold 0.5 ng/mL): pooled sensitivity 76%, specificity 69%, AUC 0.79 (systematic review)
• Bacterial vs. viral CAP: pooled sensitivity 55%, specificity 76% in one meta-analysis; a more recent multicenter study showed 81% sensitivity / 52% specificity at a cutoff of 0.1 ng/mL
• Conclusion from multiple guidelines: a single PCT value alone is insufficient to decide whether to start antibiotics; it must complement clinical evaluation

Clinical Uses

1. Sepsis Diagnosis and Risk Stratification

• Helps distinguish systemic bacterial infection from non-infectious inflammatory states
• Higher levels are associated with bacteremia, septic shock, and adverse outcomes
• Most elevated in severe, systemic bacterial infections vs. viral infections or localized bacterial infections

2. Antibiotic Stewardship - The Strongest Use Case

• Sepsis / critically ill patients: A meta-analysis of 11 trials (4,482 patients) showed:
  • Shorter antibiotic duration: 9.3 vs. 10.4 days
  • Lower 30-day mortality: 21.1% vs. 23.7% with PCT-guided care
• Acute Respiratory Infections (ARI): A patient-level meta-analysis of 6,708 patients found PCT-guided therapy reduced antibiotic exposure by 2.4 days (5.7 vs. ~8 days) with no difference in mortality
• Bottom line (Tietz Textbook): "PCT appears to be most useful when applied as a stewardship intervention with particular focus on stopping antibiotics when no longer necessary rather than being strictly used to prevent them from being started." It must be used within a systematic approach with a clearly defined algorithm.

3. Lower Respiratory Tract Infections (LRTIs) and CAP

• PCT is higher in bacterial pneumonia vs. viral pneumonia or acute COPD exacerbations
• IDSA-ATS guidelines recommend AGAINST using PCT to guide initiation of empiric antibiotics in CAP - a major clinical caveat
• A multicenter RCT of 1,656 ED patients found that providing PCT results and guidance on interpretation failed to decrease antibiotic use

4. COPD Exacerbations

• Studies show conflicting results; PCT-guided care may reduce prescriptions at initiation but does not consistently reduce overall antibiotic exposure
• One study showed higher 3-month mortality in PCT-guided ICU patients
• Uptake in the US is low (used in only ~5% of COPD hospitalizations), reflecting genuine uncertainty

5. Differentiating Infection from Inflammatory/Autoimmune Disease

• PCT is not significantly elevated in non-infectious inflammation or non-bacterial infections
• High PCT in a patient with autoimmune disease more likely indicates concomitant bacterial or fungal infection than a disease flare
• PCT has higher specificity than CRP/ESR for differentiating infection from:
  • Autoimmune flares (generally)
  • Fever after orthopaedic surgery (where CRP/ESR are non-specifically elevated)
• Exceptions (PCT can be elevated without bacterial infection):
  • Kawasaki disease
  • Goodpasture's syndrome
  • Adult-onset Still's disease
  • Granulomatosis with polyangiitis (GPA)
  • SLE flare vs. infection: data are mixed; no definitive conclusion possible
  • Acute gout flare: mixed data

6. COVID-19 Prognosis

7. Pediatric Bacteremia / Meningitis

Non-Infectious Causes of Elevated PCT (False Positives)

• Major trauma
• Major burns
• Massive ischemia / infarction
• Inhalational injury
• Heatstroke
• Severe pancreatitis
• Major surgery (post-operative)
• Advanced chronic kidney disease (chronically elevated)
• Cardiogenic shock (some degree)
• Certain autoimmune syndromes (listed above)

PCT vs. CRP - Key Comparison

2024-2025 Recent Evidence Updates

• A network meta-analysis in Crit Care Med 2024 (Kubo et al., PMID 38949476) evaluated benefits and harms of PCT- vs. CRP-guided antimicrobial discontinuation in critically ill sepsis patients - the most current head-to-head evidence
• A 2025 meta-analysis in Eur J Emerg Med (Chuang et al., PMID 40214293) directly compared diagnostic performance of PCT and CRP for sepsis - worth noting for current AUC/sensitivity figures

Fungal Infection Biomarkers

1. (1,3)-Beta-D-Glucan (BDG)

What is it?

Which fungi does it detect?

• Candida spp.
• Aspergillus spp.
• Pneumocystis jirovecii (PCP)
• Fusarium, Trichosporon, Acremonium

• Mucorales (mucormycosis) - critical exception
• Cryptococcus spp.

Cut-offs (Fungitell serum assay)

Diagnostic Performance

• Single test: pooled sensitivity 76.8%, specificity 85.3% for proven/probable IFI (heterogeneous populations)
• Two consecutive positive tests: sensitivity 49.6%, specificity 98.8% - much more specific
• For PCP specifically: sensitivity 94.8%, specificity 86.3% - the strongest use case
• BDG may be more sensitive than galactomannan for invasive aspergillosis; combining the two reduces false positives from either test alone

Guideline Positions

• IDSA: Serum BDG testing recommended for high-risk patients (haematologic malignancy, allogeneic HSCT); consider serum and/or BAL in preemptive antifungal therapy
• ESCMID: BDG alone has limited utility; recommends combining BDG with galactomannan
• Antifungal stewardship: High NPV of BDG can support de-escalation of empiric antifungal therapy - an important stewardship application

False Positives (major clinical pitfall)

Can be tested from

• Serum (standard)
• CSF
• Bronchoalveolar lavage (BAL)

2. Galactomannan (GM)

What is it?

Key Characteristics

• Positive serum antigen results typically precede clinical and radiologic features by several days
• Highly specific (when true positive) for Aspergillus - not detected in Candida, Mucor, Cryptococcus
• BAL galactomannan is more sensitive than serum GM and performs well even in patients on antifungal prophylaxis
• Sensitivity is reduced by antifungal therapy (treatment or prophylaxis)
• A positive culture supports diagnosis; PCR is faster and more sensitive than culture

Specimen and Patient Population Matters

Serial Screening

Diagnosis of Chronic vs. Acute Aspergillosis

• Acute invasive aspergillosis: antigen (GM + novel protein antigen), PCR, histology, CT (halo sign)
• Chronic pulmonary aspergillosis: Aspergillus antibody testing (precipitins / IgG) + characteristic imaging - GM antigen is not the primary tool here. A 2023 meta-analysis (de Oliveira et al., PMID 37430166) defined optimal GM cutoffs for chronic pulmonary aspergillosis
• ABPA/allergic disease: elevated total IgE + Aspergillus-specific IgE + skin-prick tests

False Positives

3. Cryptococcal Antigen (CrAg)

What is it?

1. Latex agglutination (LA): quantitative titre
2. Enzyme immunoassay (EIA)
3. Lateral flow assay (LFA): IMMY CrAg LFA - point-of-care dipstick, result in 10-20 minutes, no lab equipment needed, validated in serum or CSF

Key features

• High sensitivity and specificity in CSF for cryptococcal meningitis
• Used for serial monitoring of therapy (titre falls with successful treatment)
• LFA enables bedside testing in resource-limited settings - major advantage in HIV-endemic regions where cryptococcal meningitis is common

4. Histoplasma Antigen (Urinary/Serum)

• Detects polysaccharide antigen of Histoplasma capsulatum in urine, serum, or BAL
• Sensitivity:
  • Urine: ~90% in disseminated infection, ~80% in acute pulmonary histoplasmosis
  • BAL combined with cytopathology: adds diagnostic value
• Best for disseminated and diffuse acute pulmonary disease
• Used as primary screening test in endemic regions (Ohio/Mississippi River valleys)
• Cross-reactivity with Blastomyces, Paracoccidioides, Talaromyces can occur

5. Other Organism-Specific Antigen Tests

6. Aspergillus PCR

• Faster and more sensitive than culture for respiratory samples and blood
• Real-time PCR from BAL or serum is now widely used alongside antigen testing
• Particularly valuable when antigen testing is falsely negative (e.g., patient on antifungals)
• Sputum PCR is often strongly positive in chronic pulmonary aspergillosis

7. Metagenomic Next-Generation Sequencing (mNGS)

• Emerging technology; currently reserved for cases where standard microbiology, serology, and pathology have all failed
• Can be performed on blood, tissue, BAL
• Sensitivity and specificity vary widely by sample type and pathogen
• Expected to play a larger role in immunocompromised patients as the technology matures

Comparison Summary Table

Clinical Algorithm Approach

1. Immunocompromised host (haematology/HSCT) with fever and infiltrates:
   • Serum BDG + serum GM (serial if neutropenic, not on prophylaxis)
   • BAL GM + BAL BDG + BAL culture + PCR if bronchoscopy performed
   • CT chest (halo sign, nodules)
2. HIV / CNS presentation:
   • CSF and serum CrAg - first priority
   • Histoplasma urine Ag if endemic exposure or disseminated features
3. Suspected PCP (non-HIV immunocompromised):
   • BDG (serum) - 94.8% sensitivity; strong negative predictive value to rule out
   • BAL PCR / direct immunofluorescence
4. Suspected mucormycosis:
   • BDG and GM will be NEGATIVE - do not rely on them
   • Tissue biopsy with histology is mandatory
   • Broad aseptate ribbon-like hyphae with right-angle branching

2024-2025 Recent Evidence

• A 2024 meta-analysis in Medicine (Baltimore) (Huang et al., PMID 38306560) compared serum GM and BDG head-to-head for invasive aspergillosis diagnosis
• A 2024 Clin Microbiol Infect meta-analysis (Komorowski et al., PMID 38810927) validated CSF galactomannan for CNS aspergillosis - a newer and increasingly important indication
• A 2024 Mycoses systematic review evaluated the lateral flow galactomannan assay (IMMY Sona) in COVID-19-associated pulmonary aspergillosis (CAPA) - highlighting the growing relevance in non-classical immunosuppression